<DOC>
	<DOCNO>NCT00216138</DOCNO>
	<brief_summary>Recent progress treatment recurrent/metastatic SCCHN make introduction taxanes . Docetaxel single agent response rate 22-42 % 17 % patient recurrent disease . Capecitabine oral fluoropyrimidine prodrug convert 5-FU . Previous study show capecitabine/docetaxel combination synergistic inhibition tumor growth , result significantly superior efficacy time disease progression ( TTP ) , overall survival , median survival objective tumor response rate compare docetaxel alone . This trial investigate efficacy combination docetaxel capecitabine treat patient recurrent/metastatic SCCHN .</brief_summary>
	<brief_title>Docetaxel Capecitabine First Line Treatment Metastatic Squamous Cell Carcinoma Head &amp; Neck</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Dexamethasone antiemetic premedication1 . - Docetaxel : 60 mg/m2 60 minute infusion day 1 cycle - Capecitabine : 825 mg/m2 po BID Days 1-14 Repeat every 21 day tumor progression toxicity require discontinuation therapy Performance status : ECOG performance status 0 1 Life expectancy : At least 3 month Hematopoietic : - ANC &gt; 1,500/mm3 - Platelets &gt; 100,000/mm3 - Hemoglobin &gt; 8 gm/dl Hepatic : - Total Bilirubin Â£ ULN - Albumin &gt; 3 - Maximum Alk Phos &gt; 2.5 x &lt; 5 x ULN Renal : - Creatinine clearance &gt; 50 ml/ min ( Cockcroft-Gault ) Cardiovascular : - No decompensated congestive heart failure active angina . - Clinically significant cardiac disease well control medication ( eg . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia ) myocardial infarction past 12 month allow . Pulmonary : - Not specify</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm recurrent metastatic squamous cell carcinoma head neck . Recurrent/metastatic disease amenable surgery salvage chemoradiation . Unidimensional measurable disease accord RECIST Infield recurrence , within prior radiation field , distant metastatic disease Both infield metastatic site disease require evaluation Radiation Oncologist consider local radiation therapy first eligible possible enrollment one month completion radiation therapy . Negative pregnancy test Patients may receive prior chemotherapy part chemoradiation induction chemotherapy initial treatment disease confine head neck region Patients must fully recover prior radiation therapy Patients relapse &lt; 6 month complete combine modality curative treatment include fluoropyrimidine taxanes No brain metastases No major neurological disease , include stroke No prior chemotherapy regimen recurrent/metastatic disease No prior history capecitabine usage No prior history docetaxel usage except induction set head neck cancer complete great 6 month prior begin protocol therapy No past hypersensitivity taxanes 5 FU No hypersensitivity docetaxel drug formulate polysorbate 80 No current use warfarin Patients must receive ketoconazole , midazolam , erythromycin , orphenadrine , troleandomycin , cyclosporine antiepileptic Patients must treat follow protocol therapy within 28 day prior begin protocol therapy : sorivudine , brivudine , cimetidine , allopurinol Patients must fully recover prior surgery No known HIV seropositivity . No serious uncontrolled medical condition , uncontrolled peptic ulcer disease malabsorption syndrome No peripheral neuropathy &gt; grade 1 Patients percutaneous gastrostomy ( PEG ) must able take medication tube . No daily consumption alcohol No active infection No prior history malignancy last 5 year , exclude situ carcinoma cervix adequately treat basal squamous cell carcinoma skin Gleason Grade &lt; VII organ confine prostate cancer . No current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Head Neck Cancer</keyword>
</DOC>